A review on recent advances in lipid-based drug delivery systems for tuberculosis.

studies on isoniazid-loaded SLNs reported a 3-fold increase in LD₅₀ and a> 26-fold enhancement in bioavailability. Mannosylated clofazimine-NLCs exhibited prolonged lung retention and significantly reduced hepatic and renal toxicity. These quantitative improvements highlight the potential of lipid-based systems to outperform conventional formulations in both efficacy and safety. These advancements demonstrate strong potential for clinical translation, offering a more effective and patient-friendly approach to TB treatment.